Danaher Corporation (DHR) Covered Calls

Danaher Corporation covered calls Danaher Corporation is a global science and technology innovator committed to helping customers solve complex challenges and improving quality of life around the world. The company operates across three primary segments: Biotechnology, Life Sciences, and Diagnostics. Its world-class brands, including Cytiva, Beckman Coulter, and Cepheid, provide essential tools and services for biopharmaceutical research, clinical testing, and the development of next-generation therapeutics.

You can sell covered calls on Danaher Corporation to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for DHR (prices last updated Thu 4:16 PM ET):

Danaher Corporation (DHR) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
214.94 -5.04 205.00 217.39 5.1M 45 155
Covered Calls For Danaher Corporation (DHR)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 215 4.00 213.39 0.8% 32.4%
Mar 20 210 10.90 206.49 1.7% 16.8%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Danaher Corporation (DHR) is a global leader in life sciences and diagnostics, renowned for its "Danaher Business System" (DBS)—a culture of continuous improvement that drives operational excellence and long-term value creation. Following the strategic spin-off of its environmental business in late 2023, the company has transformed into a high-growth, pure-play life sciences and diagnostics powerhouse, focused on the most attractive end markets in healthcare and biotechnology.

Core Business and Products

  1. Biotechnology: This segment, led by the Cytiva and Pall brands, provides the "pick and shovel" infrastructure for the biopharmaceutical industry. It offers a comprehensive range of technologies for the development and manufacture of biologic drugs, including cell and gene therapies, mRNA vaccines, and monoclonal antibodies. In 2026, the company is seeing significant strength in its bioprocessing consumables as global biologic drug production scales.
  2. Life Sciences: Through brands like Leica Microsystems and SCIEX, this segment provides sophisticated analytical instruments and reagents that help researchers understand the causes of disease and identify new treatments. Innovation is currently focused on "Spatialomics," using AI-driven microscopy to map cells within their native tissue environments.
  3. Diagnostics: Featuring industry leaders like Cepheid and Beckman Coulter, this segment provides clinical instruments, software, and reagents used by hospitals and reference labs to diagnose diseases and guide treatment decisions. The company is a pioneer in "Point-of-Care" molecular testing, significantly reducing the time required to detect respiratory and gastrointestinal infections.

Competitive Landscape

Danaher operates in highly specialized markets where technical differentiation and brand loyalty are paramount. In the broad life sciences and diagnostics arena, its primary rival is Thermo Fisher Scientific. In the clinical diagnostics space, it faces intense competition from Abbott Laboratories and Agilent Technologies. For specialized genomic and proteomic research tools, it competes with Revvity and Bio-Techne. As the company integrates more AI-driven data analytics into its diagnostic workflows, it also encounters digital health and data platforms like GE HealthCare and even Google in the realm of advanced medical imaging and predictive diagnostics.

Strategic Outlook and Innovation

In 2026, the company is executing its "Biomedicine Era" strategy, placing artificial intelligence at the center of the drug discovery and diagnostic workflow. A major initiative is the "Danaher Beacon" program, which partners with top-tier academic institutions like Stanford to build next-generation smart microscopes that use AI to automate cancer drug screening. Management has formalized 2026 core revenue growth guidance of 3% to 6%, supported by a "return to normalcy" in bioprocessing equipment orders and sustained high-single-digit growth in consumables. Innovation efforts are also directed toward "Multimodal Diagnostics," which combine genetic, protein, and imaging data to provide a holistic view of patient health. By leveraging its strong free cash flow—which routinely exceeds net income—the company remains a disciplined serial acquirer, targeting high-margin, high-growth technology tuck-ins that can be optimized through the Danaher Business System.